When to use a reduced NOAC dose

Protect your patients from VTE by considering their individual risk factors and providing appropriate extended anticoagulation

© Bayer AG, 2020 | Approval number PP-M_RIVALL-0086-1

Protect your patients with cancer-associated thrombosis (CAT) with the right anticoagulant

© Bayer AG, 2020 | Approval number PP-M_RIV-ALL-0087-1

The ESC 2019 Guidelines Update on the Diagnosis and Management of Acute Pulmonary Embolism is explained by Prof. Cecilia Becattini.

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1575-1

Video to Explain the Mode of Action of Coagulation Cascade

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0090-1

Video to Explain the Mode of Action of Arterial Thrombosis

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0087-1

Prof. Craig I. Coleman gives an appreciation of the methodology used to perform Real World Evidence studies, particularly those investigating the effectiveness and safety, of non-vitamin K antagonist oral anticoagulants (or NOACs) in non-valvular atrial fibrillation patients. He also provides some key insights on what real world evidence and specifically claims databases can - and cannot - tell us

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0036-1